Vidal prompts PTAB review of Spruce patents

In a win for Neurocrine, the Patent Trial and Appeal Board has decided to review Spruce’s endocrine patents after the USPTO director intervened.

Emcure prevails against ‘fairytale’ accusations

A US biotech has failed in its bid to secure $950m in damages from an Indian generic drug maker in a dispute over COVID-19 vaccine technology.

Cassels’ new hires ‘elevate’ IP offering across US

Two new partners, who have been appointed at the Canadian law firm’s Toronto office, bring ‘extensive’ track records of success in complex patent litigation.

Daiichi Sankyo secures nearly $46m legal fees

The final award denies all claims levied at the company in a dispute involving antibody drug technology.